Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
AA, Allogene, antibody, BCR, Belgium, biochemical, Castle, circulating, clearance, conversion, copay, creation, crisaborole, de, Elrexfio, formal, Formula, free, Instance, licensee, licensure, Litfulo, LPS, meglumine, mild, nmCSPC, ORD, Poland, PRD, rapid, recurrence, refine, refused, Republic, restart, restarted, resumed, ritlecitinib, Roche, Roivant, stay, step, Stockpile, Telavant, topical, unchanged, unconditional, underinsured, uninsured, unintended, unveiled, uptake, Velsipity, Vyndamax, Zavicefta
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view